Importantly, recent results from randomized trials have shown that patients not reaching pCR may benefit from adjuvant postoperative systemic treatments, including trastuzumab emtansine in HER2‐positive BC,10 capecitabine in TNBC,11 or olaparib12 in germline BRCA‐mutated BC. The gene discussed is ERBB2; the disease is breast cancer.